SPK-843 (Aparts/Kaken).

Noer, Kasanah; Mark T, Hamann

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2005

Data sources: Europe PubMed Central

SPK-843 (Aparts/Kaken).

descriptionPublicationkeyboard_double_arrow_right Article 04 Oct 2005 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 6 (issn: 1472-4472,

Copyright policy )

Authors: Noer, Kasanah; Mark T, Hamann;

pmid: 16121692

pmc: PMC4928195

SPK-843 (Aparts/Kaken).

- Summary
- Subjects
- Metrics

Abstract

SPK-843 is a water-soluble antibiotic under co-development by Aparts and Kaken for the potential treatment of systemic fungal infections. By November 2004, SPK-843 was in phase II trials for systemic mycosis.

Related Organizations

University of Mississippi
United States

Keywords

Patents as Topic, Structure-Activity Relationship, Antifungal Agents, Clinical Trials, Phase II as Topic, Clinical Trials, Phase I as Topic, Mycoses, Animals, Humans, Polyenes

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	6
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average